Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

56.90
+0.81001.44%
Post-market: 57.360.4586+0.81%19:06 EDT
Volume:2.36M
Turnover:133.20M
Market Cap:8.71B
PE:20.55
High:57.87
Open:56.18
Low:54.70
Close:56.09
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:1.47
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:14.42
PE(LYR):20.54

Loading ...

TG Therapeutics Announces Positive Results From Phase 1 Trial Evaluating Subcutaneous Briumvi® (Ublituximab-Xiiy)

THOMSON REUTERS
·
Jun 03

TG Therapeutics - Topline Phase 3 Data for Subcutaneous Briumvi Expected Year-End 2026 or Early 2027

THOMSON REUTERS
·
Jun 03

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

GlobeNewswire
·
Jun 03

TG Therapeutics Announces Publication of Post-Hoc Data From the Phase 3 Ultimate I & Ii Trials in Treatment Naive Patients With Relapsing Forms of MS Published in Frontiers in Immunology

THOMSON REUTERS
·
Jun 01

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

GlobeNewswire
·
Jun 01

Analysts’ Top Healthcare Picks: Pfizer (PFE), TG Therapeutics (TGTX)

TIPRANKS
·
May 28

TG Therapeutics CEO to join Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28

TG Therapeutics Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
May 28

Sector Update: Health Care Stocks Mixed Premarket Wednesday

MT Newswires Live
·
May 27

TG Therapeutics reports ENHANCE trial meets primary endpoint

TIPRANKS
·
May 27

TG Therapeutics Announces Positive Topline Results From Phase 3 Enhance Trial

THOMSON REUTERS
·
May 27

TG Therapeutics Inc - Phase 3 Enhance Trial Shows Bioequivalence for Single 600 Mg Day 1 Briumvi Infusion

THOMSON REUTERS
·
May 27

TG Therapeutics Inc - Supplemental Bla Filing for Consolidated Briumvi Dosing Targeted for 2H-2026

THOMSON REUTERS
·
May 27

TG Therapeutics Inc - Single Infusion Safety Consistent With Established Briumvi Profile

THOMSON REUTERS
·
May 27

TG Therapeutics Inc: Phase 3 Trial Met Its Primary Endpoint

THOMSON REUTERS
·
May 27

TG Therapeutics Inc - Secondary Endpoints Consistent With Prior Studies; No New Safety Signals Observed

THOMSON REUTERS
·
May 27

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

GlobeNewswire
·
May 27

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

GlobeNewswire
·
May 26

How Investors May Respond To TG Therapeutics (TGTX) Boosting 2026 Guidance On Stronger Briumvi Sales

Simply Wall St.
·
May 24

TG Therapeutics Raises 2026 Outlook As Briumvi Drives Concentrated Growth

Simply Wall St.
·
May 22